Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

Pane wikiwiki

A tactical CMC checklist for peptide-based INDs under FDA's Expedited IND Pilot, covering orthogonal assays, hoʻopaʻa ʻana i ka haumia, and GMP supply.

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

ʻO ka FDA ʻO ka hoʻomaka ʻana o ka ʻimi ʻana i ka lāʻau lapaʻau hou (IND) Papahana Pilot hāʻawi i nā mea hoʻomohala biopharmaceutical i kahi manawa kūpono ʻole e hoʻolalelale i nā manawa lapaʻau mua no nā lāʻau lapaʻau kiʻekiʻe.. Eia naʻe, no nā peptides synthetic—nā pūhui e noho ana i kahi kūlana kū hoʻokahi ma waena o nā moleke liʻiliʻi a me nā mea olaola paʻakikī-ʻo nā manawa wikiwiki e hōʻike i kahi Chemistry weliweli., Hana ʻana, a me na Mana (CMC) pilikia.

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

ʻOiai hāʻawi ke alakaʻi FDA i nā maʻalahi CMC kūpono no ka First-in-Human (FIH) Māhele 1 na hoao ana, ʻAʻole nā ​​ala loiloi wikiwiki e hoʻohaʻahaʻa i ka palekana hoʻoponopono a i ʻole ka pahu kikoʻī ma lalo ʻO ke alakaʻi CMC mua o ka FDA. aka, Nānā ka poʻe loiloi FDA CDER i nā waihona peptide IND no ka hōʻailona orthogonal ikaika., hōʻike ʻana i ka haumia piha, kūpaʻa ma lalo o nā hoʻolālā lapaʻau i manaʻo ʻia, a me ka lako GMP reproducible.

No ke kōkua ʻana i ka biopharma R&D nā hui, alakaʻi papahana, a me nā luna CMC e hoʻokele i kēia puka aniani hoʻouna wikiwiki me ka ʻole o ka hoʻomaka ʻana i nā noi ʻike (IRs) a i ʻole ka mālama kino, ʻO kēia papa helu loiloi e wāwahi i nā pou CMC koʻikoʻi ʻelima i koi ʻia no kahi pūʻolo peptide IND mākaukau e nānā..

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

Pills 1: ʻIkepili & ʻO ka hoʻomaʻemaʻe ma o ka Orthogonal Assays

ʻO kahi pitfall maʻamau i nā faila peptide IND ke hilinaʻi nei i kahi ʻenehana analytical hoʻokahi - maʻamau Reversed-Phase High-Performance Liquid Chromatography. (RP-HPLC) me ka ʻike UV—e hōʻike i ka maʻemaʻe o ka lāʻau lapaʻau a me ka ʻike.

Ki Takeaway: Hōʻike maopopo ʻia nā ʻōnaehana hoʻoponopono FDA CDER a me EMA ʻaʻole lawa kahi hoʻokolohua RP-HPLC hoʻokahi e hōʻoia i ka ʻike peptide synthetic a me ka maʻemaʻe.. Pono nā hoʻouna IND e hōʻike i ka hōʻoia ʻana i ke ʻano me ka hoʻohana ʻana i ʻelua mau mea kūʻokoʻa, physicochemically orthogonal analytical method.

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

No ke aha i hāʻule ʻole ai ka hoʻāʻo RP-HPLC hoʻokahi i ka nānā hoʻoponopono

ʻOiai ʻoi aku ka maikaʻi o RP-HPLC i ka hoʻokaʻawale ʻana i nā haumia peptidic pili e pili ana i nā pilina hydrophobic, ʻAʻole hiki iā ia ke hoʻoholo i nā ʻano isobaric co-eluting, kumukānāwai isomers, a i ʻole nā ​​kaʻina holoi e kaʻana like ana i nā manawa paʻa like. Manaʻo ka poʻe loiloi i kahi matrix analytical multi-dimensional e hōʻoia i ke kaʻina kumu, nuipa pololei, uku ʻupena, a me ka stoichiometry quantitative.

Ke Hoʻolālā ʻana i kahi Panel Orthogonal Mākaukau-Naʻauao

Launa nā manaʻolana hoʻoponopono no ka hoʻāʻo ʻana i ka peptide orthogonal, Pono e hoʻohui nā kikoʻī hoʻokuʻu IND mua i kēia mau ʻano hoʻohui:

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa
  1. Hoʻoholo Hydrophobic (RP-HPLC / UHPLC): Hoʻohālikelike i ka maʻemaʻe ʻāpana-pakeneka, hoʻokumu i nā palapala chromatographic baseline, a hoʻonoho i nā paepae haumia pākahi a pau.
  2. Mass pololei & Hōʻoia Kaʻina (ESI-LC-MS/MS a i ʻole HRMS): E hōʻoia pololei i ka monoisotopic molecular kaumaha a hoʻohana i ka collision-induced dissociation (CID) ʻāpana ʻāpana (b a me y moʻo) e hōʻoia i ka papa amino acid mua.
  3. ʻIkepili ʻokoʻa o ka Uku Electrophoretic (Kapili Electrophoresis / CE): Hoʻoholo i nā huahana degradation ma muli o ka uku, e like me ka deamidation a i ʻole nā ​​hoʻololi C-terminal, hiki ke hui pū me RP-HPLC.
  4. Ka nui o Stoichiometry (ʻIkepili ʻAmina Amino / AAA): Hoʻopaʻa pololei i ka lakio amino acid a hāʻawi i kahi kūʻokoʻa, ana pololei o ka waihona peptide net (ʻokoʻa mai ka paona pauda holoʻokoʻa).

I ka hoʻokumu ʻana i nā kikoʻī hoʻokuʻu mua, pono nā mea kākoʻo e hoʻohana i nā loea kūikawā orthogonal analytical QC a me nā lawelawe hōʻailona e hōʻoia i ke ʻano kikoʻī ma mua o ka hana ʻana i nā mea hoʻokolohua lapaʻau.


Pills 2: Kiekie-Resolution Impurity Profiling & Hōʻikeʻike Kūʻai

Ma lalo o ka loiloi IND wikiwiki, pono nā mea hoʻoponopono i ka ʻike maopopo ʻana i ka ʻaoʻao o ka mea haumia lāʻau. Hoʻokumu ʻia nā peptides Synthetic ma o Solid-Phase Peptide Synthesis (SPSS) lawe i nā mea pili i ke kaʻina hana a me nā mea pili i ka huahana e pono e ʻike ʻia, helu ʻia, a i ʻike ʻia ka pilikia no ka immunogenicity.

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

SYNTHETIC PEPTIDE IMPURITY PROFILE Nā mea haumia e pili ana i nā huahana | ʻO nā mea haumia e pili ana i ke kaʻina hana • Holoi / Nā Kaʻina Hoʻopau | • Nā mea hoʻohui i koe (EDC, HOBt) • Ka hoopau ana (Asn → Asp/isoAsp) | • Koe Koe (DMF, ACN, Piperidine) • Epimerization (D/L Diastereomers)| • Ke koena Counterions (ʻO TFA vs Acetate) • Hoʻokaʻina (Met, Trp, Cys) | • Nā Metala Kaumaha & Nā mea hoʻopaʻa hoʻoheheʻe

Hooholo Holoi & Nā Kaʻina Hoʻopau

ʻO ka hui pū ʻana o ka amino acid i ka wā SPPS e hāʻawi i nā kaʻina holoi ($n-1, n-2$) a me nā peptides i ʻoki ʻia. Pono e hoʻohana ʻia ka palapala ʻāpana ʻāpana LC-MS/MS kiʻekiʻe e hoʻokaʻawale i nā koena nalo a hōʻoia ʻaʻole i ʻoi aku ka haumia hoʻokahi i ʻike ʻole ʻia ma mua o ka paepae hōʻoia ICH. (maʻamau >0.10% a i ʻole >0.15%, ma muli o ka nui o kēlā me kēia lā).

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

Hoʻopaʻa ʻana i ka Deamidation & Nā mea hoʻohaʻahaʻa hoʻoheheʻe

  • Deamidation: Asparagine (ʻO Asn) hoʻopau koke ʻia nā koena e lilo i mea waena imide cyclic, e hāʻawi ana i kahi hui o Aspartate (ʻO Asp) a me Isoaspartate (isoAsp). No ka mea, hoʻololi ka isoAsp i ka iwi kuamoʻo peptide, Pono e hōʻoia ʻia ʻo CE a i ʻole kiʻekiʻe-resolution ion-exchange chromatography e hahai i kēia ala hoʻohaʻahaʻa.
  • ʻOke ʻana: Methionine (Met), Tryptophan (Trp), a me ka Cysteine (Cys) ʻAʻole hiki ke hoʻopaʻa ʻia nā koena i ka oxidation i ka wā o ka cleavage a me ka hoʻomaʻemaʻe. Pono nā ʻano hana RP-HPLC hōʻike kūpaʻa e hoʻonā i ka sulfoxide a me ka formyl derivatives mai ka piko API makua..

ʻO ke ʻano o ka Epimerization & Racemized Diastereomers

ʻO ka racemization ma nā kikowaena alpha-carbon i ka wā o ka C-terminal activation e hoʻohua i nā diastereomers D-amino acid. (epimers). No ka mea, loaʻa i nā epimers nā paona molekala like a hui pū me ka peptide L-target ma nā kolamu RP-HPLC maʻamau., chromatography kiral, hoʻoheheʻe enzymatic, pono e hoʻohana ʻia ka spectroscopy NMR no ka helu ʻana i ka maʻemaʻe stereochemical.

Hoʻololi kūʻē TFA koena & Ka Mana Paakai

Hoʻomaʻemaʻe ʻia nā peptide me ka trifluoroacetic acid (TFA) paʻa ka TFA ma ke ʻano he counterion. No ka mea, hōʻike ʻo TFA i ka ʻawaʻawa kelepona a hiki ke hoʻololi i ke kūpaʻa preclinical, Pono nā peptides synthetic IND-grade e hoʻololi kūʻē i ka acetate a i ʻole nā ​​paʻakai chloride.

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

No ke kōkua: E wehewehe mau i ka Ion Chromatography (IC) aiʻole ^{19}F-NMR e hōʻoia i ke koena o nā pae TFA ma lalo 1.0% (w/w) i ka hailona laau lapaau hope loa.

No nā kaʻina hana paʻakikī me nā ʻāpana hydrophobic a i ʻole ka hui ʻana, ka launa pū ʻana me nā poʻe akamai i ka ka hana peptide maʻamau a me ka hoʻomaʻemaʻe hōʻoia i ka hoʻololi counterion kūpono a me ka hoʻokaʻawale kiʻekiʻe.

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

Pills 3: Paʻa Paʻa & Pākuʻi Paʻa Paʻa

No ke kākoʻo ʻana i kahi faila IND wikiwiki, Pono nā mea kākoʻo e hōʻike i ka paʻa o ka huahana lāʻau noiʻi, hikiwawe, a me ka biologically active a puni ka lōʻihi o ka hoʻokolohua lapaʻau i manaʻo ʻia.

⚠️ ʻŌlelo Aʻo: ʻO kahi kumu maʻamau o nā noi ʻike FDA ʻo ka hoʻouna ʻana i ka ʻikepili kūpaʻa i loaʻa mai ka pauka lāʻau lapaʻau maka, ma mua o ka hoʻolālā lapaʻau i manaʻo ʻia (e.g., hoʻoheheʻe wai i hoʻopaʻa ʻia i loko o ka vial/syringe hope).

Hoʻomākaukau ʻana i nā Peptide IND no ka loiloi wikiwiki ʻana o FDA: CMC papa inoa

Hōʻike Paʻa Paʻa & ʻO ka hoʻāʻo ʻana

Manaʻo ka poʻe loiloi FDA i ka ʻikepili kūpaʻa i hana ʻia ma lalo o kahi hui o nā kūlana mālama:

  • Waihona Loihi: 2°C – 8°C a i ʻole -20°C (e uhi ana i ka manawa protocol clinical i manaʻo ʻia).
  • Nā Kūlana Hoʻolalelale: 25°C / 60% RH e hoʻolālā i nā kinetics degradation.
  • Hoʻohaʻahaʻa ʻia (ʻO ka hoʻāʻo ʻana): ʻO ka ʻike ʻana i ka waika, kumu, hoʻoheheʻe peroxide, wela, a me ka photolysis. Ke hōʻoia nei kēia mau haʻawina e hōʻike ana i ka hoʻokuʻu ʻana i ke kūpaʻa maoli a hiki ke ʻike i nā mea hoʻohaʻahaʻa e kū mai ana..

Ka hoʻoheheʻe, Huihui, a me ka hui pani pani

ʻO nā peptide i loko o nā wai wai e maʻalahi i ka hui pilikino a me ka hoʻokumu ʻana i ka fibril. Pono e loiloi ka pūʻolo kūpaʻa:

  • Ka hoʻoheheʻe & Hōʻike pH: E hōʻoia ana i ka hoʻopau piha ʻana i ka pae pH physiological target me ka ʻole o ka ua.
  • Nā ʻāpana i ʻike ʻia & Huihui: Ke hoʻohana nei i ka Chromatography Hoʻokaʻawale Nui (SEK) a i ʻole ʻo Dynamic Light Scattering (DLS) e hahai i nā oligomer hiki ke hoʻoheheʻe ʻia.
  • Pākuʻi Paʻa Paʻa: Ka loiloi ʻana i ka peptide adsorption ma nā hue aniani, nā elastomers pani, a i ʻole ka paipu hāʻawi intravenous.

Pills 4: Hāʻawi hou ʻia GMP Batch & Nā Mana Hoʻomaʻemaʻe Maʻemaʻe

Hāʻawi nā papahana loiloi wikiwiki i ka hilinaʻi o ka kaulahao lako a me ka hana hou ʻana. Manaʻo ka poʻe loiloi FDA i ka hōʻoia e hiki ke hana hou ʻia ke kaʻina hana no nā ʻāpana nonclinical mua ma lalo o ka Good Manufacturing Practice. (GMP) nā kūlana no nā lako hoʻokolokolo kanaka.

E hōʻike ana i ke kūlike o ka Lot-to-Lot

Pono ka palapala IND i wikiwiki e hōʻike i ka ʻikepili hōʻiliʻili puʻupuʻu no ka liʻiliʻi ʻekolu hailona pili (e.g., ʻelua ʻāpana nonclinical/engineering a me hoʻokahi ʻāpana GMP clinical). Loaʻa nā ʻāpana hoʻohālikelike koʻikoʻi:

  • ʻĀpana-pakeneka maʻemaʻe kūlike (± 1.0%).
  • Hoʻohālikelike i nā ʻaoʻao manamana lima haumia ma nā ʻāpana he nui.
  • ʻAilikelike counterion ratio a me ka moisture content (ʻO Karl Fischer titration).

Papa 100 Nā Mana Hoʻomaʻemaʻe: ʻO ke kaumaha kino, ʻO ka maʻemaʻe, a me Endotoxin

No ka therapeutics peptide parenteral, ʻAʻole hiki ke kūʻai ʻia nā mana hana sterile. Pono ka hana ʻana i loko o ka hōʻoia Papa 100 (ISO 5) nā wahi lumi hoʻomaʻemaʻe sterile e hōʻoia i ka mālama pono ʻana i nā palena microbiological:

  • Endotoxin maʻi bacteria: <0.2 EU/mg (a i ʻole ma lalo o nā paepae e pili ana i ka maʻi kanaka no kēlā me kēia USP <85> Ho'āʻo Endotoxins Bacterial).
  • Ho'āʻo Sterility: Kūlike me USP <71> Nā ho'āʻo maʻemaʻe nā protocol kānana membrane.
  • Hoʻomalu ʻia ʻo Bioburden: Ka nānā ʻana i ka bioburden i ka wā synthesis, kānana, a me ka lyophilization no ka USP <1229> alakaʻi.

Pills 5: Pono e pili i ka pilikia no ka hoʻomaikaʻi ʻana i ke kaʻina hana ma hope o ke koho ʻana

I ka hoʻomohala wikiwiki, Hoʻololi pinepine nā kaʻina hana synthesis a me ka hoʻomaʻemaʻe ma waena o ke koho alakaʻi mua a me ka hoʻonui GMP. Hiki i nā mea kākoʻo ke hoʻololi mai ka SPPS manual i ka synthesis kahe, hoʻonui i ka cocktails cleavage, ai 'ole ka chromatography kolamu unahi mai ka grama a i ke kilo.

Koho Moho alakai (mg/g) ► Hoʻoponopono i ke kaʻina hana ► Hoʻolako GMP Clinical (g/kg)

Palapala Hoʻohālikelike Hoʻohālikelike Hoʻohālikelike Hoʻohālikelike Hoʻohālikelike ► Hoʻohālikelike Hoʻohālikelike ◄ (ICH Q5E Framework)

Hoʻokumu ʻana i kahi Kaʻina Hoʻohālikelike Kūʻē Kūʻē (I Q5E)

Ke hoʻomaikaʻi ʻia ka hana hana ma hope o ke koho ʻana, Pono nā mea kākoʻo e hoʻouna i kahi loiloi pilikia i hoʻonohonoho ʻia me Nā loina hoʻohālikelike ICH Q5E. ʻO ka pahuhopu nui, ʻo ia ka hōʻoia ʻana ʻaʻole pili ka hoʻololi ʻana i ke kaʻina hana i ka palekana o ka huahana, ikaika, a i ʻole ka maʻemaʻe.

Hoʻololi i ka hana ma hope o ke koho ʻana

  1. Hoʻohālikelike Analytical ʻaoʻao: E holo ma mua o ka hoʻololi a ma hope o ka hoʻololi ʻana ma ka papa analytical orthogonal i hōʻoia ʻia.
  2. Hoʻopaʻa ʻia ka ʻaoʻao haumia: E hōʻoia ʻaʻole ʻike ʻia nā mea haumia hou ma luna 0.10% a e noho like ana nā pae haumia i kēia manawa me ka haʻahaʻa a i ʻole ma mua o ka hoʻololi ʻana i nā ʻāpana lapaʻau.
  3. Palapala Hoʻopono Pilikino: Inā hoʻololi liʻiliʻi i ke koena counterions a i ʻole nā ​​ʻano paʻakai, hāʻawi i kahi hōʻoia i kākoʻo ʻia i ka toxicology e kikoʻī ana i ke kumu o ka hoʻololi ʻana e hōʻike ʻole ai i ka pilikia hou i ke kanaka.

Hiki i nā mea kākoʻo e ʻimi nei i ka hoʻololi ʻana i ka hoʻonui nui ke hoʻohana i ka ʻike peptide CRO kaʻina hoʻomohala a me ka hoʻonui nā pūʻulu e hoʻokumu i nā protocol hoʻohālikelike ikaika ma mua o ka hoʻouna ʻana i ka IND.


Papa Hoʻomakaukau Hoʻomaʻamaʻa no ka Peptide IND Hoʻouna

E hoʻohana i kēia matrix hōʻuluʻulu e hoʻoponopono i kāu dossier CMC ma mua o ka waiho ʻana i kāu noi e komo i ka FDA Expedited IND Pilot Program:

kia CMC Pono ʻenehana ʻenehana Ke Analytical Method Pahuhopu e ae ana / Manaʻo hoʻoponopono Kūlana
Pills 1: ʻIkepili & Maemae Ka Papahana Kumu & Mass ESI-LC-MS/MS a i ʻole HRMS Kūlike ka nuipa monoisotopic i ka manaʻo; b/y fragment ions hōʻoia i ke kaʻina [ ]
Maʻemaʻe Orthogonal RP-HPLC + CE Maʻemaʻe ʻāpana-pakeneka ≥ 95.0-98.0%; hoʻokaʻawale uku hoʻokō [ ]
Maʻiʻo Peptide ʻIkepili ʻAmina Amino (AAA) Ka nui stoichiometry; ʻike pono i ka peptide net [ ]
Pills 2: Hoʻopaʻa ʻana i ka haumia Holoi / Kaʻoki ʻana UHPLC-HRMS/MS ʻO nā mea haumia ʻike ʻole ʻia < 0.10%; hana hoʻolālā piha [ ]
Deamidation & ʻOke ʻana CE / RP-HPLC Ua helu ʻia nā mea hoʻohaʻahaʻa; hōʻoia ʻia ka hoʻokaʻawale hōʻike kūpaʻa [ ]
Nā Epimers Stereochemical ʻO Chiral LC / NMR / CD Hōʻike ʻia a mālama ʻia nā diastereomers D-amino acid [ ]
Kūʻē / TFA Ion Chromatography / ^{19}F-NMR Kūʻē kūʻē; koena TFA < 1.0% (w/w) [ ]
Pills 3: Paʻa Paʻa Paʻa RP-HPLC / SEK Hōʻoia ʻia ka hōʻike hōʻike kūpaʻa ma lalo o ka manawa maoli a me 25°C/60% RH [ ]
Hoʻohaʻahaʻa ʻia ʻAkika/Base/Heat/Lāmā/Ox. Loiloi ʻia ke koena nui; palapala ʻia nā ala degradant [ ]
Huihui & Nā ʻāpana SEK / DLS / USP <788> Hoʻomalu ʻia nā oligomers soluble; nā ʻāpana ʻike ʻia i loko o ka palena [ ]
Pills 4: GMP & ʻO ka maʻemaʻe Hoʻopuka hou ʻana o ka pūʻulu 3 Hailona Kaukahi ʻO ka hoʻololi hoʻomaʻemaʻe nui-a-lot ≤ 1.0%; pili i nā ʻaoʻao chromatographic [ ]
Nā Mana Hoʻomaʻemaʻe Papa 100 lumi hoʻomaʻemaʻe Endotoxin < 0.2 EU/mg; USP <71> sterile; mālama ʻia nā bioburden [ ]
Pills 5: Hoʻopono Kaʻina Haʻawina Hoʻohālikelike Nānā ICH Q5E Pre- vs ma hope o ka hoʻololi ʻana i hoʻohālikelike ʻia; ʻaʻohe mea haumia hou > 0.10% [ ]

Hoʻopili ʻana no nā hoʻouna ʻana i ka Peptide IND no ka nānā ʻana

ʻO ka hoʻokele ʻana i ka FDA's Expedited IND Pilot e koi ʻoi aku ma mua o ka wikiwiki - koi ia i ka maikaʻi analytical uncompromising., ʻano hoʻomaʻemaʻe ikaika, a me ka hoʻokō ʻana i ka hana sterile kīnā ʻole.

Ma ka MOL Changes, kākoʻo mākou i nā mea hoʻomohala biopharmaceutical, Nā CRO, a me nā mea noiʻi hoʻonaʻauao i ka hoʻopaʻa ʻana i ka ʻokoʻa ma waena o ke koho ʻana i nā moho a me nā lako hoʻokolohua lapaʻau. Ke hana nei i loko Papa 100 nā wahi lumi hoʻomaʻemaʻe ultra-sterile, Hāʻawi kā mākou pūnaewele peptide i hoʻohui ʻia:

  • Hoʻonui ʻia ka peptide synthesis mai ka milligrams a i ke kilo.
  • Pau 300 hoʻololi pūʻulu hana, biotinylation, hōʻailona ʻōniu, a me nā bio-conjugations paʻakikī.
  • ʻO ka pahu QC orthogonal koʻikoʻi, me ka ho'āʻo maʻemaʻe HPLC, hōʻoia kaʻina LC-MS/MS kiʻekiʻe, hoʻololi kūʻē, a me ka palapala hōʻoia piha (KoA) palapala.

Ke ʻimi nei ʻoe i kahi kaʻina peptide paʻakikī a hoʻomākaukau paha i kāu dossier CMC no ka hoʻouna wikiwiki ʻana o FDA., e ʻimi pehea e hiki ai i kā mākou ʻike loea ke hoʻopau i kāu ala hoʻoponopono. E kelepona i ka hui MOL Changes i kēia lā no ke noi ʻana i kahi kūkākūkā ʻenehana a kūkākūkā paha i ka synthesis peptide-grade maʻamau.


No ka mea kakau & Nānā ʻepekema

Mea kākau: Hoʻololi ʻo MOL i ka ʻepekema Peptide & Papa Luna Hooponopono
Mea Manaʻo ʻepekema: Ua ʻōlelo ʻo Dr. Elena Vance, Ph.D. i ke Kemika Organic
Luna Nui o CMC & Hōʻoiaʻiʻo maikaʻi ʻo Peptide, MOL Changes

Ua ʻōlelo ʻo Dr. Paʻa ʻo Vance 15 mau makahiki o ka ʻike ʻoihana i ka therapeutic peptide synthesis, hōʻoia analytical method (LC-MS/MS orthogonal, CE), a me ka hoʻoponopono CMC dossier hoʻomākaukau no ka FDA a me EMA hoʻokolokolo hoʻouna. Aia ka MOL Changes Technical Editorial Board i nā kauka lāʻau synthetic chemists, ʻepekema kālailai, a me nā loea hoʻoponopono i hoʻolaʻa ʻia i ka holomua ʻana i ka hoʻomohala ʻana i ka lāʻau peptide therapeutic a me nā kūlana maikaʻi.

Jinling Liu

Jinling Liu

Kaʻina hana R&D a me ka Mea Hana Hana Kaʻike kumu: Hoʻonui kaʻina hana, kemika ʻōmaʻomaʻo, hoʻomaikaʻi maikaʻi, Hoʻokō ka hana GMP.

Pilikino: He loea ʻo Jinling Liu i ka unuhi ʻana o nā lāʻau peptide mai ka pālākiō keʻena (pae milligram) i ka hana pāʻoihana (pae kilokani). Ua kūpaʻa ʻo ia i ka hōʻemi nui ʻana i nā kumukūʻai hana peptide a me ka hōʻemi ʻana i ka pollution kaiapuni ma o ka hoʻonui ʻana i nā kūlana cleavage., ka hoʻomaikaʻi ʻana i nā lakio o nā condensation reagents, a me ka hoʻolauna ʻana i ka ʻenehana synthesis kahe mau. Ua alakaʻi ʻo ia i ka optimization o nā papahana peptide he nui, ka loaʻa ʻana o ke kumu kūʻai haʻahaʻa, hoʻomaʻemaʻe kiʻekiʻe ma ka pālākiō 100-kilogram.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana